Alamea Verwaltungs GmbH Acquires New Holdings in Masimo Corporation $MASI

Key Points

• Alamea Verwaltungs GmbH has invested approximately $327,000 in 1,963 shares of Masimo Corporation, according to a recent 13F filing.
• Masimo's stock price opened at $139.71, with a market cap of $7.59 billion and expected EPS for the current fiscal year at 4.1.
• Following the latest earnings report, Masimo reported a 7.7% revenue increase year-over-year, with an EPS of $1.33, exceeding estimates by $0.11.

Alamea Verwaltungs GmbH purchased a new position in Masimo Corporation (NASDAQ:MASI - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,963 shares of the medical equipment provider's stock, valued at approximately $327,000.

Other large investors have also bought and sold shares of the company. Massachusetts Financial Services Co. MA grew its holdings in shares of Masimo by 13.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider's stock valued at $327,842,000 after buying an additional 232,671 shares during the last quarter. Nuveen LLC acquired a new position in shares of Masimo during the first quarter valued at about $25,830,000. GAMMA Investing LLC grew its holdings in shares of Masimo by 26,284.3% during the first quarter. GAMMA Investing LLC now owns 122,951 shares of the medical equipment provider's stock valued at $20,484,000 after buying an additional 122,485 shares during the last quarter. BLI Banque de Luxembourg Investments acquired a new position in shares of Masimo during the fourth quarter valued at about $17,067,000. Finally, Bank of Nova Scotia acquired a new position in shares of Masimo during the first quarter valued at about $15,528,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Masimo news, Director William R. Jellison purchased 3,000 shares of the stock in a transaction dated Monday, August 11th. The shares were bought at an average price of $145.98 per share, with a total value of $437,940.00. Following the completion of the transaction, the director directly owned 4,790 shares in the company, valued at approximately $699,244.20. This trade represents a 167.60% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 16.90% of the stock is currently owned by company insiders.

Masimo Stock Performance

MASI stock traded down $0.97 during mid-day trading on Wednesday, hitting $136.77. The company had a trading volume of 536,772 shares, compared to its average volume of 840,914. The firm has a market cap of $7.43 billion, a PE ratio of -16.05 and a beta of 1.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. Masimo Corporation has a 12 month low of $107.98 and a 12 month high of $194.88. The stock's fifty day moving average price is $155.30 and its two-hundred day moving average price is $160.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 EPS for the quarter, topping the consensus estimate of $1.22 by $0.11. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $370.90 million for the quarter, compared to analyst estimates of $368.65 million. During the same quarter in the previous year, the firm posted $0.86 earnings per share. The company's revenue for the quarter was up 7.7% on a year-over-year basis. On average, analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MASI has been the topic of several analyst reports. BTIG Research restated a "buy" rating on shares of Masimo in a report on Thursday, August 14th. Wall Street Zen cut shares of Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Wells Fargo & Company cut their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Raymond James Financial cut their price target on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler boosted their price target on shares of Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Masimo currently has a consensus rating of "Moderate Buy" and a consensus target price of $193.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.